Please login to the form below

Not currently logged in

Nobel laureate Dr Walter Gilbert joins Amylyx Pharmaceuticals

He takes up a seat on the company's board of directors

Amylyx Dr Walter GilbertThe founder and former chief executive officer of Biogen Dr Walter Gilbert has been elected to Amylyx Pharmaceuticals' board of directors.

The US-based pharmaceutical firm specialises in developing disease-modifying treatments for neurodegenerative diseases, including Amyotrophic Lateral Sclerosis (ALS).

Justin Klee, co-founder and president of Amylyx, said: “Dr Gilbert brings an enormous breadth of experience as a scientist, biotech founder and executive.

“We are honoured that he will join our efforts to advance AMX0035 for the treatment of ALS, which will be tested in an initial clinical trial in patients later this year.”

Over his 40-year career in industry and academia, Dr Gilbert founded several life sciences companies, including Biogen where he was chief executive officer and chairman of the board between 1981 and 1985, and Myriad Genetics where he continues to serve as vice chairman of its board of directors.

Dr Gilbert received the Nobel Prize in Chemistry in 1980 for the development of a rapid method of DNA sequencing, and is currently the Carl M. Loeb University Professor Emeritus at Harvard University.

He said: “Amylyx has assembled an outstanding team that is advancing an innovative approach to ALS and other neurodegenerative diseases.

“I am excited to help bring this promising therapeutic to patients.”

26th January 2016

From: Research



Featured jobs

Subscribe to our email news alerts


Add my company

WE ARE COUCH – a full service medical communications agency. We are a trusted partner; always striving to help make...

Latest intelligence

How to get rep buy-in for multi-channel
How do you manage a team who may be resistant to change?...
Blog: Digital therapeutics: within our reach?
Digital therapeutics is a hot topic right now. By using digital technology to manage, treat or even prevent chronic conditions, digital therapeutics is promising to revolutionise healthcare. But is this...
figure 1
The valuable brand
Creating value beyond the pill is both possible and increasingly necessary...